Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Cancer Aggressiveness”

48 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 48 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07218666
What this trial is testing

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

Who this might be right for
Aggressive Variant Prostate Carcinoma
Deepak Kilari 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04592237
What this trial is testing

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
M.D. Anderson Cancer Center 120
Not applicableStudy completedNCT01672411
What this trial is testing

Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer

Who this might be right for
Prostate Cancer
University Of Perugia 250
Not applicableActive Not RecruitingNCT01464216
What this trial is testing

MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness

Who this might be right for
Prostatic NeoplasmsGenital Neoplasms, MaleProstatic Diseases
Oslo University Hospital 120
Not applicableUnknownNCT04283032
What this trial is testing

Impact of Magnetic Resonance and Biomarkers for Screening for Prostate Cancer. Cost-effectiveness Analysis

Who this might be right for
Establish the Efficacy Between the Four Schemes in Terms of the Aggressiveness of the Tumors According to the Gleason ClassificationEstablish the Efficacy Between the Four Schemes in Terms of Morbidity Associated With the TechniqueEstablish the Efficacy Between the Four Schemes in Terms of the Patient's Subjective Perception Regarding Pain and Quality of Life+4 more
InvestigatorUrologyIBSAL
Testing effectiveness (Phase 2)Active Not RecruitingNCT03809000
What this trial is testing

Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery

Who this might be right for
Prostate Cancer
RTOG Foundation, Inc. 188
Not applicableStudy completedNCT03289130
What this trial is testing

Dietary Factors and Racial Disparities in Prostate Cancer Aggressiveness

Who this might be right for
Prostatic Neoplasm
University of South Carolina 2,258
Not applicableStudy completedNCT01347476
What this trial is testing

Aggressive Prostate Cancers in Elderly Patients

Who this might be right for
Prostatic Neoplasms
Seoul National University Hospital 1,333
Not applicableEnded earlyNCT03256630
What this trial is testing

Evaluation of a Blood Biomarker to Try and Distinguish Between the Presence or Absence of Aggressive Prostate Cancer

Who this might be right for
Prostate Cancer
Genomic Health®, Inc. 128
Not applicableLooking for participantsNCT04052048
What this trial is testing

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

Who this might be right for
Prostate Cancer Aggressiveness
Immunis.AI 2,000
Testing effectiveness (Phase 2)Looking for participantsNCT07179783
What this trial is testing

Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)

Who this might be right for
Prostate Cancer (Adenocarcinoma)Prostate Cancer Metastatic Castration-ResistantProstate Adenocarcinoma With Neuroendocrine Differentiation
Tianjin Medical University Second Hospital 28
Not applicableStudy completedNCT04593420
What this trial is testing

Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.

Who this might be right for
Prostate Cancer
Ipsen 817
Not applicableLooking for participantsNCT05539677
What this trial is testing

Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research

Who this might be right for
Malignant Solid TumorsPrimary Brain TumorMelanoma+4 more
N.N. Petrov National Medical Research Center of Oncology 1,000
Not applicableStudy completedNCT02689271
What this trial is testing

CombIning advaNces in imagiNg With biOmarkers for improVed Diagnosis of Aggressive prosTate cancEr

Who this might be right for
Prostate Cancer
University College, London 365
Not applicableTemporarily pausedNCT05064111
What this trial is testing

Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy

Who this might be right for
Prostate CancerProstate Adenocarcinoma
University of Arizona 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03263650
What this trial is testing

Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC

Who this might be right for
Prostate Cancer AggressivenessProstate Carcinoma
M.D. Anderson Cancer Center 96
Not applicableLooking for participantsNCT04472338
What this trial is testing

Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study

Who this might be right for
Prostate Carcinoma
University of Washington 450
Not applicableStudy completedNCT03397160
What this trial is testing

Pioneering Advances in Care and Education (PACE)

Who this might be right for
Decision Support Systems, ClinicalProstate Cancer
University of California, San Francisco 119
Not applicableStudy completedNCT03232411
What this trial is testing

Biobank for African American Prostate Cancer Research in Florida

Who this might be right for
Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute 592
Testing effectiveness (Phase 2)Study completedNCT05005728
What this trial is testing

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer
Xencor, Inc. 72
Load More Results
628